Rib-X Pharmaceuticals, Inc. Reports Preclinical Studies at ICAAC With Novel Classes of RX-04 Antibiotic Compounds Demonstrating Potent and Rapid Efficacy in a S. pneumoniae Lung Model of Infection and Activity Against a Diverse Spectrum of Biodefense Pathogens
9/12/2012 10:17:01 AM
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc. announced today the presentation of five posters featuring completely new antibiotic compounds from the company’s RX-04 program at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 9-12, 2012 in San Francisco, CA. The reported data from multiple preclinical studies emphasized the potent, broad spectrum activity of RX-04 compounds, including at single, low doses. A study conducted in a Streptococcus pneumoniae lung infection model established the potential for this class of compounds to address respiratory pathogens. Additionally, studies demonstrated the unique activity of these novel antibiotics across a diverse array of bacterial pathogens, including against carbapenem- and colistin-resistant strains of Klebsiella pneumoniae and five major biodefense pathogens.